These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7456470)

  • 21. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient.
    Aruna AS; Murungi JH
    Ann Pharmacother; 2005 Jun; 39(6):1131-5. PubMed ID: 15840734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH; Gelder MG
    Br J Clin Pharmacol; 1979 Dec; 8(6):565-70. PubMed ID: 533577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Depressive syndromes during schizophrenic psychoses].
    Müller P
    Fortschr Med; 1978 Aug; 96(30):1518-20. PubMed ID: 669548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
    McCreadie RG; Dingwall JM; Wiles DH; Heykants JJ
    Br J Psychiatry; 1980 Dec; 137():510-7. PubMed ID: 7011468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma levels of fluphenazine and prolactin in psychiatric patients.
    Kitamura T; McGovern DA; Imlah NW; Wiles D; Schiff AA
    Eur Arch Psychiatry Neurol Sci; 1988 Sep; 237(6):320-6. PubMed ID: 3181218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
    Wiles DH; McCreadie RG; Whitehead A
    Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of schizophrenic psychoses by sustained-action neuroleptics in psychiatric outpatients' treatment (author's transl)].
    Polácek J
    Cesk Psychiatr; 1982 Feb; 78(1):49-55. PubMed ID: 7060182
    [No Abstract]   [Full Text] [Related]  

  • 28. The prolactin response in patients receiving neuroleptic therapy. The effect of fluphenazine decanoate.
    Dotti A; Lostia O; Rubino IA; Bersant G; Carilli L; Zorreta D
    Prog Neuropsychopharmacol; 1981; 5(1):69-77. PubMed ID: 7280130
    [No Abstract]   [Full Text] [Related]  

  • 29. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daytime variation in serum prolactin level in patients receiving oral and depot antipsychotic medication.
    Goode DJ; Meltzer HY; Fang VS
    Biol Psychiatry; 1981 Jul; 16(7):653-62. PubMed ID: 7196775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
    Schulz SC; Thompson PA; Jacobs M; Ninan PT; Robinson D; Weiden PJ; Yadalam K; Glick ID; Odbert CL
    J Clin Psychiatry; 1999 Jun; 60(6):366-72. PubMed ID: 10401914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical observation on the effect of domestic fluphenazine decanoate in the treatment of schizophrenia---report of 431 cases (author's transl)].
    Zhang YF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1981 Aug; 14(3):182-5. PubMed ID: 7333179
    [No Abstract]   [Full Text] [Related]  

  • 33. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
    Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
    J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haloperidol and droperidol treatment in schizophrenics. Clinical application of the "prolactin-model".
    Langer G; Pühringer W
    Acta Psychiatr Belg; 1980; 80(5):574-83. PubMed ID: 7234451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
    Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.
    Altamura AC; Curry SH; Montgomery S; Wiles DH
    Psychopharmacology (Berl); 1985; 87(1):30-3. PubMed ID: 3933035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate.
    Wiles D; Franklin M; Dencker SJ; Johansson R; Lundin L; Malm U
    Psychopharmacology (Berl); 1980; 71(2):131-6. PubMed ID: 6777812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic and pharmacodynamic studies on high doses of fluphenazine.
    Dencker SJ; Johansson R; Malm U
    Psychopharmacology (Berl); 1988; 94(2):237-41. PubMed ID: 3127851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolactin bioassay in schizophrenia before and after neuroleptics.
    Peabody CA; Warner MD; Griffin M; Boutros NN; Worsley IG; Friesen HG
    Psychiatry Res; 1992 Mar; 41(3):249-55. PubMed ID: 1594711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum and cerebrospinal fluid prolactin patterns during neuroleptic treatment in schizophrenic patients.
    Rimón R; Kampman R; Laru-Sompa R; Heikkilä L
    Pharmacopsychiatry; 1985 May; 18(3):252-4. PubMed ID: 4011674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.